Enzene Biosciences, a biotech company based in Pune, India, will open its state-of-the-art biopharmaceutical manufacturing plant on the Princeton West Innovation Campus in Hopewell, according to a Thursday announcement from Choose New Jersey.
As part of Enzene’s expansion plans, the company will initially hire 50 employees and grow to 300 employees at its New Jersey facility. Operations in the new facility, the company’s first location outside of India, are expected to begin in June 2024.
As a contract development and manufacturing organization, Enzene Biosciences provides services to global pharmaceutical companies, partnering with them in their drug development and manufacturing processes.
“The strong relationship between New Jersey and India has gained increasing momentum since we opened the New Jersey India Center to cultivate economic opportunities during our trip to the country in 2019,” Gov. Phil Murphy said.
“We are so proud to welcome Enzene to New Jersey’s thriving life sciences ecosystem,” Wesley Mathews, CEO and president of Choose New Jersey, said. “Yet another Indian biopharma company has established itself in the state, demonstrating the strength of the New Jersey-India economic partnership. Beyond economic and commercial ties, our academic and cultural connections make it the perfect fit for Indian companies looking to expand to North America. Enzene’s growth in this sector highlights New Jersey’s global presence throughout all areas of the biopharmaceutical industry — from clinical trials to large-scale manufacturing.”
“Enzene Biosciences is thrilled to establish our manufacturing operations in New Jersey, as it allows us to extend our local manufacturing capabilities to our valued North American clients,” Dr. Himanshu Gadgil, CEO of Enzene Biosciences, said. “We are excited to provide them with access to our cutting-edge continuous manufacturing platform, which enables streamlined and efficient production processes. New Jersey’s highly skilled workforce, state-of-the-art infrastructure and renowned academic institutions make it an ideal location for Enzene, ensuring that we can deliver exceptional services and support to our clients in the U.S.”
New Jersey has long been acknowledged as a national leader in life sciences, and Enzene’s expansion is yet another example of Indian companies finding their footing in the state.
Choose New Jersey met representatives from Enzene during a business attraction mission to India in 2022. Enzene’s successful expansion was supported by Choose New Jersey, the New Jersey Israel Center, Reed Smith and JLL.
Enzene, with assistance from Choose New Jersey, connected with in-state partners, including construction firms, human resources and payroll services, business insurance providers, township leadership and universities. Reed Smith facilitated Enzene’s legal needs, and JLL Capital Markets represented the property.
Enzene’s local manufacturing capabilities will provide North American biopharmaceutical companies with streamlined supply chains, fast turnaround times, enhanced communication, and greater control over the manufacturing process. By providing comprehensive manufacturing capabilities under one roof.
